Literature DB >> 23053471

Muscle fiber-type distribution, fiber-type-specific damage, and the Pompe disease phenotype.

L E M van den Berg1, M R Drost, G Schaart, J de Laat, P A van Doorn, A T van der Ploeg, A J J Reuser.   

Abstract

Pompe disease is a lysosomal storage disorder caused by acid α-glucosidase deficiency and characterized by progressive muscle weakness. Enzyme replacement therapy (ERT) has ameliorated patients' perspectives, but reversal of skeletal muscle pathology remains a challenge. We studied pretreatment biopsies of 22 patients with different phenotypes to investigate to what extent fiber-type distribution and fiber-type-specific damage contribute to clinical diversity. Pompe patients have the same fiber-type distribution as healthy persons, but among nonclassic patients with the same GAA mutation (c.-32-13T>G), those with early onset of symptoms tend to have more type 2 muscle fibers than those with late-onset disease. Further, it seemed that the older, more severely affected classic infantile patients and the wheelchair-bound and ventilated nonclassic patients had a greater proportion of type 2x muscle fibers. However, as in other diseases, this may be caused by physical inactivity of those patients.

Entities:  

Mesh:

Year:  2012        PMID: 23053471     DOI: 10.1007/s10545-012-9541-7

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  34 in total

1.  A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease.

Authors:  Priya S Kishnani; Wuh-Liang Hwu; Hanna Mandel; Marc Nicolino; Florence Yong; Deyanira Corzo
Journal:  J Pediatr       Date:  2006-05       Impact factor: 4.406

Review 2.  The comparative utility of serum creatine kinase versus serum aldolase in the evaluation of muscle disorders.

Authors:  D Giesker; G N Bowers
Journal:  Conn Med       Date:  1979-11

Review 3.  Developmental changes in creatine kinase and aldolase isoenzymes and their possible function in association with contractile elements.

Authors:  D C Turner; H M Eppenberger
Journal:  Enzyme       Date:  1973

Review 4.  The natural course of non-classic Pompe's disease; a review of 225 published cases.

Authors:  Léon P F Winkel; Marloes L C Hagemans; Pieter A van Doorn; M Christa B Loonen; Wim J C Hop; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2005-08       Impact factor: 4.849

5.  Muscle fiber types and morphometric analysis of skeletal msucle in six-year-old children.

Authors:  R D Bell; J D MacDougall; R Billeter; H Howald
Journal:  Med Sci Sports Exerc       Date:  1980       Impact factor: 5.411

6.  Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

Authors:  P S Kishnani; D Corzo; M Nicolino; B Byrne; H Mandel; W L Hwu; N Leslie; J Levine; C Spencer; M McDonald; J Li; J Dumontier; M Halberthal; Y H Chien; R Hopkin; S Vijayaraghavan; D Gruskin; D Bartholomew; A van der Ploeg; J P Clancy; R Parini; G Morin; M Beck; G S De la Gastine; M Jokic; B Thurberg; S Richards; D Bali; M Davison; M A Worden; Y T Chen; J E Wraith
Journal:  Neurology       Date:  2006-12-06       Impact factor: 9.910

7.  Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited.

Authors:  B G H Schoser; J Müller-Höcker; R Horvath; K Gempel; D Pongratz; H Lochmüller; W Müller-Felber
Journal:  Neuropathol Appl Neurobiol       Date:  2007-06-15       Impact factor: 8.090

8.  Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease.

Authors:  Maarten R Drost; Gert Schaart; Paul van Dijk; Carine I van Capelle; Ger J van der Vusse; Tammo Delhaas; Ans T van der Ploeg; Arnold J J Reuser
Journal:  Muscle Nerve       Date:  2008-02       Impact factor: 3.217

9.  Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.

Authors:  Léon P F Winkel; Joep H J Kamphoven; Hannerieke J M P van den Hout; Lies A Severijnen; Pieter A van Doorn; Arnold J J Reuser; Ans T van der Ploeg
Journal:  Muscle Nerve       Date:  2003-06       Impact factor: 3.217

Review 10.  Human aging, muscle mass, and fiber type composition.

Authors:  J Lexell
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1995-11       Impact factor: 6.053

View more
  7 in total

Review 1.  Skeletal muscle fiber type: using insights from muscle developmental biology to dissect targets for susceptibility and resistance to muscle disease.

Authors:  Jared Talbot; Lisa Maves
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2016-05-19       Impact factor: 5.814

2.  Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe disease.

Authors:  Gerben J Schaaf; Tom J M van Gestel; Esther Brusse; Robert M Verdijk; Irenaeus F M de Coo; Pieter A van Doorn; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  Acta Neuropathol Commun       Date:  2015-10-28       Impact factor: 7.801

3.  TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle.

Authors:  Yohei Sato; Hiroshi Kobayashi; Takashi Higuchi; Yohta Shimada; Hiroyuki Ida; Toya Ohashi
Journal:  Mol Ther Methods Clin Dev       Date:  2016-08-10       Impact factor: 6.698

4.  Muscle mass, structural and functional investigations of senescence-accelerated mouse P8 (SAMP8).

Authors:  An Yun Guo; Kwok Sui Leung; Parco Ming Fai Siu; Jiang Hui Qin; Simon Kwoon Ho Chow; Ling Qin; Chi Yu Li; Wing Hoi Cheung
Journal:  Exp Anim       Date:  2015-07-17

5.  Chest MRI to diagnose early diaphragmatic weakness in Pompe disease.

Authors:  Laurike Harlaar; Pierluigi Ciet; Gijs van Tulder; Alice Pittaro; Harmke A van Kooten; Nadine A M E van der Beek; Esther Brusse; Piotr A Wielopolski; Marleen de Bruijne; Ans T van der Ploeg; Harm A W M Tiddens; Pieter A van Doorn
Journal:  Orphanet J Rare Dis       Date:  2021-01-07       Impact factor: 4.123

6.  Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.

Authors:  Sean N Prater; Trusha T Patel; Anne F Buckley; Hanna Mandel; Eugene Vlodavski; Suhrad G Banugaria; Erin J Feeney; Nina Raben; Priya S Kishnani
Journal:  Orphanet J Rare Dis       Date:  2013-06-20       Impact factor: 4.123

7.  Genotype-phenotype correlation in Pompe disease, a step forward.

Authors:  Paola De Filippi; Kolsoum Saeidi; Sabrina Ravaglia; Andrea Dardis; Corrado Angelini; Tiziana Mongini; Lucia Morandi; Maurizio Moggio; Antonio Di Muzio; Massimiliano Filosto; Bruno Bembi; Fabio Giannini; Giovanni Marrosu; Miriam Rigoldi; Paola Tonin; Serenella Servidei; Gabriele Siciliano; Annalisa Carlucci; Claudia Scotti; Mario Comelli; Antonio Toscano; Cesare Danesino
Journal:  Orphanet J Rare Dis       Date:  2014-08-08       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.